FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 64 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $49,000 | +188.2% | 14,743 | +171.8% | 0.00% | +300.0% |
| Q3 2019 | $17,000 | +21.4% | 5,425 | -10.2% | 0.00% | 0.0% |
| Q2 2019 | $14,000 | -73.6% | 6,038 | -56.8% | 0.00% | -66.7% |
| Q1 2019 | $53,000 | +5200.0% | 13,991 | +3819.0% | 0.00% | – |
| Q4 2018 | $1,000 | -80.0% | 357 | -57.7% | 0.00% | – |
| Q3 2018 | $5,000 | -89.1% | 843 | -90.8% | 0.00% | -100.0% |
| Q2 2018 | $46,000 | +1050.0% | 9,209 | +1074.6% | 0.00% | – |
| Q1 2018 | $4,000 | -82.6% | 784 | -83.9% | 0.00% | -100.0% |
| Q2 2017 | $23,000 | -25.8% | 4,872 | -21.6% | 0.00% | 0.0% |
| Q1 2017 | $31,000 | +933.3% | 6,218 | +2177.7% | 0.00% | – |
| Q4 2016 | $3,000 | -93.6% | 273 | -96.3% | 0.00% | -100.0% |
| Q2 2016 | $47,000 | +2250.0% | 7,455 | +2543.6% | 0.00% | – |
| Q1 2016 | $2,000 | -81.8% | 282 | -79.2% | 0.00% | -100.0% |
| Q4 2015 | $11,000 | -73.8% | 1,358 | -76.3% | 0.00% | -50.0% |
| Q3 2015 | $42,000 | -52.8% | 5,738 | -65.0% | 0.00% | -60.0% |
| Q3 2014 | $89,000 | – | 16,393 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $24,530,000,000 | 3.64% |
| Opaleye Management Inc. | 950,000 | $4,873,000 | 1.39% |
| DSC Advisors, L.P. | 1,187,604 | $6,092,000 | 1.28% |
| DAFNA Capital Management LLC | 335,500 | $1,721,000 | 0.84% |
| Vivo Capital, LLC | 855,000 | $4,386,000 | 0.62% |
| Stonepine Capital Management, LLC | 129,756 | $666,000 | 0.36% |
| Eversept Partners, LP | 107,500 | $551,475 | 0.26% |
| Tekla Capital Management LLC | 930,398 | $4,773,000 | 0.19% |
| Perceptive Advisors | 1,117,324 | $5,732,000 | 0.16% |
| Crestline Management, LP | 217,670 | $1,117,000 | 0.14% |